The African meningitis belt, which stretches from Senegal in the west to Ethiopia in the east, has historically experienced large-scale outbreaks of meningitis every 7-14 years. These epidemics have resulted in significant morbidity and mortality. Traditional polysaccharide vaccines were not providing long-lasting immunity, and there was an urgent need for a more effective solution. Thus, MenAfriVac was developed to provide long-term immunity and reduce the occurrence of these outbreaks.
